🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

206 results for “Glaxo” Clear

  1. 0.9% Sodium Chloride for Injection, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  2. A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 other active

    1 trial

  3. A placebo matching Mepolizumab, Nucala 100 mg solution for injection in pre-filled syringe, A placebo matching Depemokimab, GSK3511294, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection, Nucala 100 mg solution for injection in pre-filled syringe, Fasenra 30 mg solution for injection in pre-filled syringe

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 small molecule active

    1 trial

  4. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  5. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  6. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  7. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  8. Belantamab mafodotin

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  9. Benlysta 200 mg solution for injection in pre-filled pen.

    GlaxoSmithKline

    connective tissue diseases

    phase 3 small molecule active

    1 trial

  10. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes.

    GlaxoSmithKline

    Lung Diseases, Interstitial

    phase 3 small molecule active

    1 trial

  11. Bepirovirsen

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial

  12. Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed)

    GlaxoSmithKline

    Invasive meningococcal disease (IMD)

    phase 3 small molecule active

    1 trial

  13. Cervarix™

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 mab completed

    1 trial

  14. Dexa 8 mg inject JENAPHARM Injektionslösung, VELCADE 3.5 mg powder for solution for injection, Dexamethason 8 mg GALEN® Tabletten, Dexamethasone Tablets BP 2.0mg, Dexamethasone 2mg Tablets, Dexa-ratiopharm® 8 mg Injektionslösung, DARZALEX 20 mg/mL concentrate for solution for infusion, Dexamethason 8 mg JENAPHARM®

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  15. Dexamethason 8 mg GALEN® Tabletten, Imnovid 1 mg hard capsules, Dexamethasone 2mg Tablets, Dexamethason 8 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, Imnovid 4 mg hard capsules

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  16. Dostarlimab

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  17. Eltrombopag

    GlaxoSmithKline

    Non-alcoholic Steatohepatitis

    phase 3 small molecule terminated

    1 trial

  18. Expanded access program for mepolizumab in subjects with hypereosinophilic syndrome.

    GlaxoSmithKline

    Hypereosinophilic Syndrome

    phase 3 other active

    1 trial

  19. FF

    GlaxoSmithKline

    Rhinitis, Allergic, Perennial

    phase 3 small molecule completed

    1 trial

  20. FF/GW642444 Inhalation Powder

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    2 trials

  21. FF/UMEC/VI

    GlaxoSmithKline

    Asthma

    phase 3 small molecule active

    1 trial

  22. FluLaval® Quadrivalent

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  23. Fluticasone furoate

    GlaxoSmithKline

    Rhinitis

    phase 3 small molecule completed

    1 trial

  24. GSK 2132231A

    GlaxoSmithKline

    Melanoma

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources